
ValiRx - VAL201 Clinical Trial Update
VAL Wed, 30 Sep 2020, 09:00am BST
Dr Suzy Dilly, Chief Executive Officer provides an update on the headline results from the recently completed Phase 1/2 clinical trial of its lead asset VAL201, for the treatment of advanced prostate cancer, held at University College Hospital, London.

Suzanne Dilly, Chief Executive Officer
Thu, 14 Jul 2022, 1:30pm BST
Suzanne Dilly, Chief Executive Officer
Thu, 30 Jun 2022, 11:00am BST
Management Team, ValiRx PLC
Wed, 6 Apr 2022, 5:00pm BST
Suzanne Dilly, Chief Executive Officer
Wed, 23 Mar 2022, 12:56pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 5 Jan 2022, 12:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 20 Dec 2021, 12:20pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 26 Nov 2021, 4:48pm GMT
Suzanne Dilly, Chief Executive Officer
Tue, 2 Nov 2021, 5:00pm GMT
Suzanne Dilly, Chief Executive Officer
Fri, 28 May 2021, 12:30pm BST
Suzanne Dilly, Chief Executive Officer
Mon, 15 Feb 2021, 12:00pm GMT
Dr Suzanne Dilly and Dr Kevin Cox
Tue, 8 Dec 2020, 2:00pm GMT
Suzanne Dilly, Chief Executive Officer
Mon, 30 Nov 2020, 3:30pm GMT
Suzanne Dilly, Chief Executive Officer
Wed, 30 Sep 2020, 9:00am BST
Suzanne Dilly, Chief Executive Officer
Wed, 8 Jul 2020, 3:15pm BST
Dr George Morris, Chief Operating Officer
Wed, 11 Sep 2019, 4:10pm BST
Victoria D'Aquino, Research and Development Officer
Thu, 4 Jul 2019, 9:00am BST
Dr George Morris, Chief Operating Officer
Thu, 20 Jun 2019, 12:20pm BST
Dr George Morris, Chief Operating Officer
Thu, 2 May 2019, 1:16pm BST